Enanta Pharmaceuticals, Inc.
ENTAHealthcare|Biotechnology|US
$11.00
+0.92 (+9.13%)
Tangible Book / Share
$3.47
Cash / Share
$6.51
Clinical Trials (46)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07908381 A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe Disease | RSV | P2P3 | Recruiting | 860 | RCT, Double-blind | zelicapavir, Placebo |
| NCT07482657 A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus | RSV Infection, RSV | P2 | Recruiting | 150 | RCT, Double-blind | zelicapavir, Placebo |
| NCT07540910 A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults | Chronic Inducible Urticaria, Chronic Spontaneous Urticaria | P1 | Recruiting | 98 | RCT, Double-blind | EDP-978, Placebo |
| NCT03421431 A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis | Non-Alcoholic Steatohepatitis | P2 | Completed | 134 | RCT, Double-blind | EDP-305 Dose 1, EDP-305 Dose 2, Placebo |
| NCT05568706 A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications. | RSV Infection | P2 | Completed | 187 | RCT, Double-blind | EDP-938, Placebo |
| NCT03691623 A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model | RSV Infection | P2 | Completed | 179 | RCT, Double-blind | EDP-938 Dose 1, EDP-938 Dose 2, Placebo, EDP-938 Dose 3, EDP-938 Dose 4, Placebo |
| NCT04816721 A Study to Evaluate EDP 938 Regimens in Children With RSV | Respiratory Syncytial Virus (RSV) | P2 | Completed | 99 | RCT, Double-blind | EDP-938, Placebo |
| NCT05616728 A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19 | COVID-19 | P2 | Completed | 231 | RCT, Double-blind | EDP-235, Placebo |
| NCT04378010 A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH | Non-Alcoholic Steatohepatitis | P2 | Terminated | 98 | RCT, Double-blind | EDP-305 1.5 mg, EDP-305 2 mg, Placebo |
| NCT00270517 Comparative Study of EDP-420 Versus Another Antibiotic in the Treatment of Community Acquired Pneumonia | Community Acquired Pneumonia | P2 | Unknown | 250 | RCT, Double-blind | EDP-420 / Duration of Treatment - 3 days, Telithromycin / Duration of Treatment - 7 days |
| NCT06170242 A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model | RSV Infection | P2 | Completed | 142 | RCT, Double-blind | EDP-323 Dose Regimen 1, EDP-323 Dose Regimen 2, Placebo |
| NCT04196101 A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects | Respiratory Syncytial Virus | P2 | Completed | 82 | RCT, Double-blind | EDP-938, Placebo |
| NCT03394924 A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis | Primary Biliary Cholangitis | P2 | Completed | 68 | RCT, Double-blind | EDP-305 1 mg, EDP-305 2.5 mg, Placebo |
| NCT04633187 Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract | Respiratory Syncytial Virus Infections | P2 | Terminated | 9 | RCT, Double-blind | EDP-938, Placebo |
| NCT03187496 Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers. | NASH | P1 | Completed | 24 | Open-label | Midazolam, Caffeine, Rosuvastatin, EDP-305 |
| NCT03207425 A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers | NASH | P1 | Completed | 29 | Open-label | EDP 305 |
| NCT02173574 Two-way Interaction Between Alisporivir and EDP239 | Hepatitis C Virus | P1 | Completed | 42 | Open-label | DEB025, EDP239 |
| NCT01856426 Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects | Hepatitis C | P1 | Completed | 28 | RCT, Double-blind | EDP239, Placebo |
| NCT03750383 Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects | RSV Infection | P1 | Completed | 48 | Open-label | EDP-938, EDP-938, Cyclosporine, Prednisone |
| NCT04971512 A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION. | Chronic Hepatitis B Virus Infection | P1 | Terminated | 26 | RCT, Double-blind | EDP-721, Placebo (Part 1), EDP-721 (Part 2), Placebo (Part 2), EDP-514, Placebo (Part 2) |
| NCT03213145 Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers | NASH - Nonalcoholic Steatohepatitis | P1 | Completed | 48 | Open-label | intraconazole, Rifampin, EDP 305 |
| NCT04008004 A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2) | Chronic HBV Infection | P1 | Completed | 99 | RCT, Double-blind | EDP-514, Placebo |
| NCT01999725 Evaluation of the Safety and Pharmacokinetics of a Single Oral Dose of EDP-788 | Safety in Normal Volunteers | P1 | Completed | 80 | RCT, Double-blind | EDP-788, Placebo |
| NCT05587478 A Study of EDP-323 in Healthy Subjects | RSV Infection | P1 | Completed | 82 | RCT, Double-blind | EDP-323, Placebo |
| NCT05594602 Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects. | COVID-19 | P1 | Completed | 36 | Open-label | EDP-235, EDP-235, EDP-235, Itraconazole, Carbamazepine, Quinidine |
| NCT02255968 Evaluation of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of EDP-788 | Healthy | P1 | Terminated | 16 | RCT, Double-blind | EDP-788, Placebo |
| NCT04470388 A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment | Chronic HBV Infection | P1 | Completed | 25 | RCT, Double-blind | EDP-514, Placebo |
| NCT03755778 Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects | RSV Infection | P1 | Completed | 72 | Open-label | EDP-938, EDP-938, EDP-938, Itraconazole, Rifampin, Quinidine |
| NCT04559126 A Study of EDP-297 in Healthy Subjects | NASH - Nonalcoholic Steatohepatitis With Liver Fibrosis | P1 | Completed | 82 | RCT, Double-blind | EDP-297, Placebo |
| NCT04498741 Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects | RSV Infection | P1 | Completed | 89 | Open-label | EDP-938, EDP-938, EDP-938, Tacrolimus, Dabigatran, Rosuvastatin, EDP-938, Midazolam |
| NCT06917508 A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants | RSV Infection, Drug Drug Interaction | P1 | Completed | 24 | Open-label | EDP-323, Midazolam, Caffeine, Rosuvastatin |
| NCT04783753 Drug-Drug Interaction Study Between EDP-514, Itraconazole, Carbamazepine, and Quinidine in Healthy Subjects | Hepatitis B | P1 | Completed | 72 | Open-label | EDP-514, EDP-514, EDP-514, Itraconazole, Carbamazepin, Quinidine |
| NCT03610945 Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers | NASH - Nonalcoholic Steatohepatitis | P1 | Completed | 48 | Open-label | Fluconazole, Quinidine, EDP-305, EDP-305 |
| NCT04871724 Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects | RSV Infection | P1 | Completed | 24 | Open-label | EDP-938, Fluconazole |
| NCT05594615 Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects | COVID-19 | P1 | Completed | 24 | Open-label | EDP-235, Midazolam, Rosuvastatin, Caffeine |
| NCT06601192 A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults | RSV Infection, QTc Interval | P1 | Completed | 72 | RCT, Double-blind | zelicapavir (therapeutic dose), zelicapavir (supratherapeutic dose), Placebo, moxifloxacin |
| NCT05246878 A Study of EDP-235 in Healthy Subjects | SARS CoV 2 Infection | P1 | Completed | 72 | RCT, Double-blind | EDP-235, Placebo |
| NCT04927793 Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects | Respiratory Syncytial Virus (RSV) | P1 | Completed | 8 | Open-label | EDP-938 |
| NCT03783897 A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects | NASH - Nonalcoholic Steatohepatitis | P1 | Completed | 43 | Open-label | EDP-305, Oral Contraceptive |
| NCT06847464 A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323. | RSV Infection, Drug Drug Interaction (DDI) | P1 | Completed | 48 | Open-label | EDP-323, Itraconazole, EDP-323, carbamazepine, EDP-323, Quinidine, EDP-323, fluconazole |
| NCT00989872 Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers | Skin and Soft Tissue Infections, Methicillin-resistant Staphylococcus Aureus | P1 | Completed | 67 | RCT, Double-blind | EDP-322 |
| NCT03748628 Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects | NASH - Nonalcoholic Steatohepatitis | P1 | Completed | 8 | Open-label | EDP-305 |
| NCT02652377 EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients | Hepatitis C | P1 | Completed | 100 | RCT, Double-blind | EDP-494, Placebo |
| NCT03384823 A Study of EDP-938 in Healthy Subjects | RSV Infection | P1 | Completed | 90 | RCT, Double-blind | EDP-938, Placebo |
| NCT00990145 Multiple Ascending-Dose Study of EDP 322 in Healthy Adult Volunteers | MRSA, SSTI | P1 | Completed | 52 | RCT, Double-blind | EDP-322 |
| NCT02918929 A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD | Presumptive NAFLD | P1 | Completed | 146 | RCT, Double-blind | EDP 305, Placebo |